Printed from Voxsanity (voxsanity.com.au) — NCT07720167 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07720167
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue sample, at a specific early stage (cT1c or T2a) with no sign the cancer has spread to nearby lymph nodes, based on the AJCC 9th Edition staging system.
- People whose cancer showed a certain level of activity on a PET scan (a type of imaging test), and/or whose tissue sample showed the cancer is moderately to poorly differentiated or undifferentiated (terms describing how the cancer cells look under a microscope).
- People whose lung function tests show their lungs would be able to handle the planned surgery, with specific breathing measurements (FEV1 and DLCO) predicted to remain above 40% after the operation.
- People who have been assessed by a surgeon as suitable for surgery and have adequate overall organ function, as recorded in their medical record.
- People who have an ECOG Performance Status of 0 or 1, meaning they are fully active or have only minor restrictions in physically demanding activity (confirm with trial site).
- People who have signed and dated a consent form approved by an ethics review board before any trial-related procedures begin.
- People who are older than 18 years of age.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a known ALK gene mutation in their cancer.
- People who have a known EGFR gene mutation in their cancer.
- People who have a known or suspected active autoimmune disease (a condition where the immune system attacks the body) that has required medication to suppress the immune system within the past two years. People with type 1 diabetes, an underactive thyroid managed only with hormone replacement, certain skin conditions not needing systemic treatment, or conditions unlikely to return without a specific trigger may still be considered.
- People who have previously been treated with chemotherapy or other cancer therapies, including certain immunotherapy drugs that target specific immune system pathways (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 treatments).
- People who have had another cancer that was active within the past 3 years, unless it was a type considered easily curable and apparently resolved, such as certain skin cancers, early bladder cancer, or non-invasive cancers of the prostate, cervix, or breast.
- People who have a history of symptomatic interstitial lung disease (a condition causing scarring or inflammation in the lungs that caused symptoms).
- People who are currently imprisoned or being held involuntarily or under compulsory order for treatment of a psychiatric or physical illness.
- People who have previously had a bone marrow transplant.
- People who have a known allergy or history of hypersensitivity to the study drug or any of its ingredients.
- People with certain heart or cardiovascular conditions, including moderate-to-severe heart failure (classified as Class II, III, or IV by the New York Heart Association system), a heart attack or acute coronary event within the past 12 months, or a mini-stroke or stroke within the past year.
- People who require ongoing use of corticosteroid or immune-suppressing medication above a certain dose (more than 10 mg of prednisone per day or equivalent) within one week before the first dose of study medication. People who only need a very short course of steroids (up to 2 days in the week before joining) or who take steroids to replace hormones the body does not produce naturally may still be considered.
- People who have had an infection serious enough to require hospitalisation or treatment with intravenous (IV) antibiotics or antifungals within 2 weeks before the first dose of study medication.
- People with a known diagnosis of HIV, hepatitis B, hepatitis C, an immune deficiency condition, or tuberculosis (whether active or dormant).
- People who have received a live vaccine within 4 weeks before starting the study medication, or a COVID-19 vaccine within 1 week before the planned start of study medication (or where planned COVID-19 vaccinations would not be completed at least 1 week before starting).
- Women who are able to become pregnant, and men, who are unwilling to use highly effective contraception from before the first dose, throughout the study, and for at least 6 months after the last dose. Accepted methods include certain hormonal contraception, intrauterine devices, permanent surgical procedures, a vasectomised partner (as sole sexual partner with confirmed surgical success), or complete sexual abstinence throughout the entire risk period. Methods such as periodic abstinence, withdrawal, spermicides alone, or the lactational amenorrhoea method are not accepted. Using both a male and female condom together is also not accepted. Male participants must use condoms or abstain from sex (unless vasectomised with confirmed success), and must not donate sperm during this period. Pregnancy testing is required for women who are able to become pregnant; it is not required for postmenopausal women or those who have had a hysterectomy or tubal ligation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 843-792-9321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 November 2026
Est. completion
1 November 2029
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Frequency and percentage of patients with a pathologic complete response (pCR) rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.